These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16170894)

  • 1. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
    Clapp K
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of transplant in multiple myeloma.
    Barlogie B
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):604-6. PubMed ID: 16167043
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
    Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
    J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
    Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
    Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
    Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem bone marrow transplantation in multiple myeloma.
    Chng WJ
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
    [No Abstract]   [Full Text] [Related]  

  • 10. New developments in conditioning regimens before auto-SCT in multiple myeloma.
    Moreau P; Attal M; Harousseau JL
    Bone Marrow Transplant; 2011 Jul; 46(7):911-5. PubMed ID: 21358678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
    SanMiguel J; Facon T; Cavo M
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204
    [No Abstract]   [Full Text] [Related]  

  • 12. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Harousseau JL; Moreau P
    N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
    Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
    Tricot G; Barlogie B; Zangari M; van Rhee F; Hoering A; Szymonifka J; Cottler-Fox M
    Haematologica; 2008 Nov; 93(11):1739-42. PubMed ID: 18728024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.
    Martino M; Olivieri A; Offidani M; Vigna E; Moscato T; Fedele R; Montanari M; Console G; Gentile M; Messina G; Irrera G; Morabito F
    Expert Opin Investig Drugs; 2013 May; 22(5):619-34. PubMed ID: 23550793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autologous stem cell transplantation in multiple myeloma - pro].
    Goldschmidt H
    Dtsch Med Wochenschr; 2009 Sep; 134(39):1942. PubMed ID: 19760555
    [No Abstract]   [Full Text] [Related]  

  • 20. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
    Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.